{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:08:10Z","timestamp":1790075290380,"version":"4.0.1"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cervical cancer remains a leading cause of cancer-related mortality among women worldwide, with approximately 30\u201340% of patients experiencing recurrence after definitive chemoradiotherapy for locally advanced disease. The concept of minimal residual disease (MRD)\u2014the persistence of viable tumor clones after curative-intent treatment that escape conventional radiographic and clinical detection\u2014has transformed surveillance and treatment paradigms in hematological malignancies and, increasingly, in solid tumors. In cervical cancer, the near-universal association with high-risk human papillomavirus (HPV) provides a unique molecular handle for MRD detection: circulating tumor HPV DNA (ctHPV DNA) released into the bloodstream by residual tumor cells. Here, we review three interconnected dimensions of MRD in cervical cancer. First, we examine the biological basis of tumor persistence after chemoradiotherapy, encompassing HPV integration-driven genomic instability, immune evasion within the irradiated tumor microenvironment, and clonal repopulation kinetics. Second, we synthesize the rapidly maturing evidence for ctHPV DNA-guided post-treatment surveillance, from digital PCR and next-generation sequencing-based detection platforms to prospective clinical validation studies demonstrating that detectable ctHPV DNA after chemoradiotherapy independently predicts recurrence with lead times of 3\u20136 months before radiographic progression. Third, we evaluate emerging recurrence-directed intervention strategies, including MRD-stratified treatment intensification (immune checkpoint inhibition and therapeutic HPV vaccination), adoptive cell therapy, and how integrating ctHPV DNA dynamics with immunotherapeutic approaches may define a new framework for personalized post-treatment management in this molecularly tractable malignancy.<\/jats:p>","DOI":"10.3389\/fonc.2026.1938965","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:50:56Z","timestamp":1790074256000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Minimal residual disease in cervical cancer: biological persistence, ctHPV DNA-guided surveillance, and recurrence-directed intervention"],"prefix":"10.3389","volume":"16","author":[{"given":"Jing","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ninghai Maternal and Child Health Hospital","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teng","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ninghai Maternal and Child Health Hospital","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyue","family":"Sheng","sequence":"additional","affiliation":[{"name":"Department of Traditional Chinese Medicine, Maternity & Child Care Center Of DeZhou","place":["Dezhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Thoracic Surgery, Ninghai First Hospital","place":["Ningbo, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13163968","article-title":"Liquid biopsy in cervical cancer: Hopes and pitfalls","volume":"13","author":"Cafforio","year":"2021","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00147-x","article-title":"Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial","volume":"24","author":"Mileshkin","year":"2023","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/nejm199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/S0020-7292(06)60030-1","article-title":"Carcinoma of the cervix uteri. FIGO 26th annual report on the results of treatment in gynecological cancer","volume":"95","author":"Quinn","year":"2006","journal-title":"Int J Gynaecol Obstet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.19.2289","article-title":"Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma","volume":"298","author":"Schwarz","year":"2007","journal-title":"JAMA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/(sici)1096-9896(199909)189:1<12::aid-path431>3.0.co;2-f","article-title":"Human papillomavirus is a necessary cause of invasive cervical cancer worldwide","volume":"189","author":"Walboomers","year":"1999","journal-title":"J Pathol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10071525","article-title":"Circulating HPV DNA in the management of oropharyngeal and cervical cancers: Current knowledge and future perspectives","volume":"10","author":"Krasniqi","year":"2021","journal-title":"J Clin Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1186\/s12967-025-06470-x","article-title":"Human papilloma virus (HPV) mediated cancers: an insightful update","volume":"23","author":"Baba","year":"2025","journal-title":"J Transl Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: From basic studies to clinical application","volume":"2","author":"zur Hausen","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2019.03116","article-title":"Human papillomavirus E6 and E7: The cervical cancer hallmarks and targets for therapy","volume":"10","author":"Pal","year":"2019","journal-title":"Front Microbiol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00954","article-title":"Clinical validation of human papilloma virus circulating tumor DNA for early detection of residual disease after chemoradiation in cervical cancer","volume":"42","author":"Han","year":"2024","journal-title":"J Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02444","article-title":"Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer","volume":"38","author":"Chera","year":"2020","journal-title":"J Clin Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1219","article-title":"Spatiotemporally deciphering the mysterious mechanism of persistent HPV-induced Malignant transition and immune remodelling from HPV-infected normal cervix, precancer to cervical cancer: Integrating single-cell RNA-sequencing and spatial transcriptome","volume":"13","author":"Guo","year":"2023","journal-title":"Clin Transl Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-023-02233-x","article-title":"Detection of circulating cell-free HPV DNA of 13 HPV types for patients with cervical cancer as potential biomarker to monitor therapy response and to detect relapse","volume":"128","author":"Mittelstadt","year":"2023","journal-title":"Br J Cancer"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70282","article-title":"Ultrasensitive next-generation sequencing-based detection of circulating human papillomavirus DNA for cervical cancer recurrence monitoring","volume":"132","author":"B\u00f8nl\u00f8kke","year":"2026","journal-title":"Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"3701","DOI":"10.3390\/ijms26189214","article-title":"From viral infection to genome reshaping: The triggering role of HPV integration in cervical cancer","volume":"26","author":"Li","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/v9080206","article-title":"Somatic host cell alterations in HPV carcinogenesis","volume":"9","author":"Litwin","year":"2017","journal-title":"Viruses"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.9093","article-title":"Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells","volume":"33","author":"Stevanovi\u0107","year":"2015","journal-title":"J Clin Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.pvr.2017.12.006","article-title":"Therapeutic vaccines for high-risk HPV-associated diseases","volume":"5","author":"Chabeda","year":"2018","journal-title":"Papillomavirus Res"},{"key":"B21","volume-title":"Radiobiology for the Radiologist","author":"Hall","year":"2019"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2256","article-title":"Models, mechanisms and clinical evidence for cancer dormancy","volume":"7","author":"Aguirre-Ghiso","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"B23","article-title":"Association between tumor hypoxia and Malignant progression in advanced cancer of the uterine cervix","volume":"56","author":"H\u00f6ckel","year":"1996","journal-title":"Cancer Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"78","DOI":"10.3892\/ol.2025.15375","article-title":"Cervical cancer immune microenvironment: Mechanisms of HPV-mediated immune evasion and advances in immunotherapy (Review)","volume":"31","author":"Zhou","year":"2026","journal-title":"Oncol Lett"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-06-3388","article-title":"High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer","volume":"67","author":"Piersma","year":"2007","journal-title":"Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.05028-11","article-title":"Epithelial cell responses to infection with human papillomavirus","volume":"25","author":"Stanley","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod Pathol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2014.07.005","article-title":"Radiotherapy and immunogenic cell death","volume":"25","author":"Golden","year":"2015","journal-title":"Semin Radiat Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs629","article-title":"Combining radiotherapy and cancer immunotherapy: A paradigm shift","volume":"105","author":"Formenti","year":"2013","journal-title":"J Natl Cancer Inst"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-14-3511","article-title":"TGF\u03b2 is a master regulator of radiation therapy-induced antitumor immunity","volume":"75","author":"Vanpouille-Box","year":"2015","journal-title":"Cancer Res"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2004.02.044","article-title":"Recurrent squamous cell carcinoma of cervix after definitive radiotherapy","volume":"60","author":"Hong","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3793","article-title":"Mechanisms of disseminated cancer cell dormancy: An awakening field","volume":"14","author":"Sosa","year":"2014","journal-title":"Nat Rev Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3802\/jgo.2026.37.e99","article-title":"Type-specific detection and quantification of circulating tumor HPV DNA by digital PCR in surgically resected cervical cancer","volume":"37","author":"Matsunaga","year":"2026","journal-title":"J Gynecol Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.00585-25","article-title":"Detection, quantitation, and genotyping of human papillomavirus circulating tumor DNA by droplet digital PCR","volume":"63","author":"Fernholz","year":"2025","journal-title":"J Clin Microbiol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aan2415","article-title":"Direct detection of early-stage cancers using circulating tumor DNA","volume":"9","author":"Phallen","year":"2017","journal-title":"Sci Transl Med"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1789","article-title":"Circulating mutant DNA to assess tumor dynamics","volume":"14","author":"Diehl","year":"2008","journal-title":"Nat Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-05077-3","article-title":"Digital droplet PCR-based quantification of ccfHPV-DNA as liquid biopsy in HPV-driven cervical and vulvar cancer","volume":"149","author":"Thangarajah","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6377","article-title":"Predictive impact of human papillomavirus circulating tumor DNA in treatment response monitoring of HPV-associated cancers; a meta-analysis on recurrent event endpoints","volume":"12","author":"Karimi","year":"2023","journal-title":"Cancer Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1136\/ijgc-2023-004873","article-title":"Circulating cell-free DNA as a diagnostic and prognostic marker for cervical cancer","volume":"34","author":"Parida","year":"2024","journal-title":"Int J Gynecol Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0224001","article-title":"Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis","volume":"15","author":"Gu","year":"2020","journal-title":"PloS One"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01480-21","article-title":"Detection of circulating HPV16 DNA as a biomarker for cervical cancer by a bead-based HPV genotyping assay","volume":"10","author":"Galati","year":"2022","journal-title":"Microbiol Spectr"},{"key":"B43","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.3390\/ijms262110503","article-title":"Liquid biopsy biomarkers for cervical cancer: A systematic review","volume":"26","author":"Pineda-Migranas","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B44","doi-asserted-by":"publisher","first-page":"11266","DOI":"10.1038\/s41598-025-93152-9","article-title":"Prognostic value of circulating HPV cell-free DNA in cervical cancer using liquid biopsy","volume":"15","author":"Gupta","year":"2025","journal-title":"Sci Rep"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.31557\/apjcp.2025.26.5.1681","article-title":"Quantification of circulating HPV DNA as a biomarker for cervical pre-cancer and cancer: A pilot study","volume":"26","author":"Gangwar","year":"2025","journal-title":"Asian Pac J Cancer Prev"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.7554\/elife.101887","article-title":"Monitoring circulating cell-free HPV DNA in metastatic or recurrent cervical cancer: Clinical significance and treatment implications","volume":"14","author":"Yin","year":"2025","journal-title":"Elife"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1097\/ppo.0000000000000769","article-title":"The role of circulating tumor DNA (ctDNA) in the treatment of human papilloma virus-positive (HPV+) oropharyngeal squamous cell carcinoma","volume":"31","author":"Qian","year":"2025","journal-title":"Cancer J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2012.01.015","article-title":"High-risk human papillomavirus testing versus cytology in predicting post-treatment disease in women treated for high-grade cervical disease: A systematic review and meta-analysis","volume":"125","author":"Kocken","year":"2012","journal-title":"Gynecol Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01438-7","article-title":"Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE): an international, multicentre, randomised phase 3 trial","volume":"404","author":"McCormack","year":"2024","journal-title":"Lancet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"346ra92","DOI":"10.1126\/scitranslmed.aaf6219","article-title":"Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer","volume":"8","author":"Tie","year":"2016","journal-title":"Sci Transl Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2200075","article-title":"Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer","volume":"386","author":"Tie","year":"2022","journal-title":"N Engl J Med"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01808-7","article-title":"Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"404","author":"Lorusso","year":"2024","journal-title":"Lancet"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00479-5","article-title":"Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial","volume":"24","author":"Monk","year":"2023","journal-title":"Lancet Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: Results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1309748","article-title":"Improved survival with bevacizumab in advanced cervical cancer","volume":"370","author":"Tewari","year":"2014","journal-title":"N Engl J Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2112187","article-title":"Survival with cemiplimab in recurrent cervical cancer","volume":"386","author":"Tewari","year":"2022","journal-title":"N Engl J Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.tvr.2022.200238","article-title":"Cervical cancer therapies: Current challenges and future perspectives","volume":"13","author":"Burmeister","year":"2022","journal-title":"Tumour Virus Res"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0810097","article-title":"Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia","volume":"361","author":"Kenter","year":"2009","journal-title":"N Engl J Med"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-11-88","article-title":"HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial","volume":"11","author":"van Poelgeest","year":"2013","journal-title":"J Transl Med"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI80009","article-title":"Therapeutic cancer vaccines","volume":"125","author":"Melief","year":"2015","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.29309","article-title":"mRNA-HPV vaccine encoding E6 and E7 improves therapeutic potential for HPV-mediated cancers via subcutaneous immunization","volume":"95","author":"Lee","year":"2023","journal-title":"J Med Virol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1001\/jamaoncol.2018.4051","article-title":"Combining immune checkpoint blockade and tumor-specific vaccine for patients with incurable human papillomavirus 16-related cancer: A phase 2 clinical trial","volume":"5","author":"Massarelli","year":"2019","journal-title":"JAMA Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-14-3341","article-title":"Targeting of HPV-16+ epithelial cancer cells by TCR gene engineered T cells directed against E6","volume":"21","author":"Draper","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1056\/nejmoa2313811","article-title":"Tisotumab vedotin as second- or third-line therapy for recurrent cervical cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-07-1880","article-title":"Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine","volume":"14","author":"Welters","year":"2008","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-2384","article-title":"HPV sequencing facilitates ultrasensitive detection of HPV circulating tumor DNA","volume":"27","author":"Leung","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.8671","article-title":"Circulating tumor DNA analysis in patients with cancer: American Society of Clinical Oncology and College of American Pathologists joint review","volume":"36","author":"Merker","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1938965\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T10:50:57Z","timestamp":1790074257000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1938965\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":70,"alternative-id":["10.3389\/fonc.2026.1938965"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1938965","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1938965"}}